Adalvo has been recognised with two prestigious awards at the 2024 Global Generics & Biosimilars Bulletin Awards: Business Development of the Year and Value Added Medicine of the Year.
The Business Development of the Year award recognises our strong focus on delivering high-quality products and services to partners. Our success includes developing one of the broadest diabetes portfolios in the industry, with products like Liraglutide pre-filled pen, set to launch in Europe this year, and Semaglutide, with market entries planned for Canada, Brazil, and Saudi Arabia.
The Value Added Medicine Initiative of the Year award highlights our commitment to improving patient care with differentiated solutions. Products like Dalbavancin RTD, Pregabalin ER tablets, and Lisdexamfetamine Oral Solution are designed to meet unmet medical needs, enhance treatment outcomes, and simplify patient care.
Anil Okay, CEO of Adalvo, commented, "These awards are a clear reflection of our team's dedication to growth and commitment. We are proud to be recognised for our efforts in business development and our commitment to delivering value-added medicines that make a difference for patients."
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!